Achieve Life Sciences Study Links Cytisinicline's Receptor Selectivity to Low Nausea Rates — Achieve Life Sciences, Inc.

Event summary

Achieve Life Sciences published a study in Nicotine & Tobacco Research on March 26, 2026, detailing cytisinicline's receptor selectivity profile.
The study found cytisinicline binds strongly to the α4β2 nicotinic receptor (99% displacement) but minimally to the 5-HT3 receptor (-8% displacement), which may explain its low nausea rates.
The FDA has assigned a PDUFA date of June 20, 2026, for cytisinicline's NDA for smoking cessation.
Voluntary survey data from the ORCA-OL study showed high quit and reduction rates of nicotine use with few side effects.

The big picture

Achieve Life Sciences' study provides a mechanistic explanation for cytisinicline's favorable tolerability profile, which could differentiate it in the smoking cessation market. The FDA's upcoming decision on the NDA will be critical, as the last approval in this category was over two decades ago. With nearly half of U.S. smokers and vapers wanting to quit, the potential market for an effective, well-tolerated therapy is substantial.

What we're watching

Regulatory Approval: Whether the FDA will approve cytisinicline for smoking cessation by the June 20, 2026 PDUFA date.
Market Potential: The pace at which cytisinicline can capture market share in the smoking cessation space, given the lack of new FDA-approved treatments in 20 years.
Clinical Efficacy: How the minimal 5-HT3 receptor interaction will translate into real-world tolerability and adherence rates for patients.